Abstract: The present invention is directed to pharmaceutical compositions of 7-(acryloyl)indoles, such as 4,5 -Dichloro-thiophene-2-sulfonic acid [(E)-3-[1-(2,4-dichlorophenylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]-acryloyl]amide (DTSI), having a structure shown below. The invention is also directed to methods of treatment utilizing formulations of the DTSI and processes of preparation of the formulations.
Type:
Application
Filed:
May 15, 2007
Publication date:
May 29, 2008
Applicant:
DECODE GENETICS, EHF.
Inventors:
Jasbir Singh, Matt Shaoming Duan, Thorsteinn Thorsteinsson, Mitchell B. Friedman, Mark Gurney
Abstract: A chemical genus of biphenyl heterocycle derivative inhibitors of LTA4H (leukotriene A4 hydrolase) of the formula: is disclosed. In these compounds Q and Z are (CH2)1-10; in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(?O)— or —C?O(NH)—; Het is a 5-7 membered non-aromatic nitrogen heterocycle; and W is acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl, or substituted heterocyclyl, or taken together ZW can be H or —COOalkyl. The compounds are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Application
Filed:
August 2, 2007
Publication date:
April 17, 2008
Applicant:
DECODE GENETICS EHF.
Inventors:
Vincent Sandanayaka, Pushpa Chandrasekar, Mark Gurney
Abstract: Two chemical genera of pyrazolylphenyl and pyrrolylphenyl derivatives are disclosed. They have the general formula: In these compounds ring (a) is a pyrazole or pyrrole; Q is selected from the group consisting of a direct bond, O, S, SO, SO2, NR1, CH2, CF2, and C(O); HET is a 4-7-membered saturated nitrogenous heterocycle; and taken together ZW is H or Z is (CH2)1-10 in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(?O)— or —C?O(NH)—; and W is hydrogen, acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl or substituted heterocyclyl. The compounds are inhibitors of LTA4H (leukotriene A4 hydrolase). They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Application
Filed:
August 3, 2007
Publication date:
February 7, 2008
Applicant:
deCODE genetics ehf.
Inventors:
Vincent Sandanayaka, Jasbir Singh, Lei Zhao, Peng Yu, Mark E. Gurney
Abstract: The present invention relates to a chemical genus of 3-(triaryl)-2-aminopropanol derivative inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention of inflammatory diseases and disorders.
Type:
Application
Filed:
August 3, 2007
Publication date:
February 7, 2008
Applicant:
DECODE GENETICS EHF.
Inventors:
Vincent Sandanayaka, Jasbir Singh, David Sullins, Mark Gurney
Abstract: The present invention is directed to methods for diagnosing psychiatric disorders in an individual. The methods described herein are directed to determining the orientation of the Inv8p23 inversion fragment by determining the gene expression of informative genes in the Inv8p23 genomic region.
Abstract: The invention relates to methods for inducing a pro-asthma/pro-inflammatory like state in a resident tissue cell, comprising contacting the cell with one or more cytokines, e.g., IL-1?, TNF? or both. Methods are also disclosed for identifying genes that regulate responses to anti-inflammatory drugs, to methods for drug screening, and to methods for identifying genes that correlate with various pro-asthma/pro-inflammatory disease phenotypes.
Type:
Grant
Filed:
December 22, 2004
Date of Patent:
July 17, 2007
Assignees:
deCODE genetics ehf., The Children's Hospital of Philadelphia
Abstract: The present invention relates to the usage pattern, commonly found in many software applications, of defining sets of objects based on object attributes. A specifically designed set definition language for defining sets, called SDL, is described and a software system that implements this language efficiently on top of a standard relational database management system (RDBMS) is presented. The unique features of the SDL language are the implicit constraints that are enforced on the relational data that belong to the objects. Unique to the SDL system is also the logical metadata of dimensions that enables the SDL system to enforce these constraints across relations. The SDL system utilizes several optimization techniques to enable efficient implementation on top of RDBMS. It is also shown how the SDL language and the SQL language can be merged with bidirectional inlining using syntactic gates. Query composition tools are also described that facilitate the creation of SDL expressions.
Type:
Grant
Filed:
June 24, 2003
Date of Patent:
December 19, 2006
Assignee:
deCODE Genetics ehf.
Inventors:
Hakon Gudbjartsson, Thorvaldur S. Arnarson, Pavol Rovensky, Vilmundur Palmason
Abstract: Methods are disclosed for predicting the efficacy of a drug for treating an inflammatory disease in a human patient, including: obtaining a sample of cells from the patient; obtaining a gene expression profile of the sample in the absence and presence of in vitro modulation of the cells with specific cytokines and/or mediators; and comparing the gene expression profile of the sample with a reference gene expression profile, wherein similarities between the sample expression profile and the reference expression profile predicts the efficacy of the drug for treating the inflammatory disease in the patient.
Abstract: A system for editing the dimension structure associated with a data cube is revealed. The editing may be used to enforce given criteria on the cube. This includes modifying the cube in order to satisfy regulations requiring researchers to protect information about individuals, such as medical, genealogy and genetics records. The inference control methods disclosed therefore enable safe aggregated datasets to be released to researchers. When combined with information theoretic methods, the invention method of editing the dimension structures may be used to express clearly and discover correlations that exist in the dataset. This mining of the data and editing of the dimension structure allows the user of a simple multidimensional cube viewer to visually verify the patterns discovered.
Abstract: The invention relates to improved materials and methods for therapy to inhibit production of leukotrienes, and all therapeutic applications thereof.
Abstract: The invention provides a number of methods for enhancing the aqueous solubility of an active ingredient which is insoluble or sparingly soluble in water. In one preferred embodiment, solubilization of the active ingredient is enhanced by combining it with ?-cyclodextrin in an aqueous complexation medium comprising ?-cyclodextrin and a negatively- or positively-charged compound which forms an inclusion or non-inclusion complex with ?-cyclodextrin and its inclusion complexes.
Abstract: The invention discloses methods and apparatus that facilitate efficient querying of tables referencing semistructured data such as digraphs and other domains with complex grouping structure. The invention methods enable meaningful indexing of the tables as well as rewriting of queries with respect to the structures. Dynamic schema extraction using proper coloring algorithms is disclosed that structures the semistructured data in such a way that complex set operations and grouping are replaced with traditional relational joins. This enables a relational database system to harness its entire query optimizing capability when querying tables referencing semistructured data.
Abstract: Methods for diagnosis of asthma or a susceptibility to asthma based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. Also methods for treatment of asthma or a susceptibility to asthma based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. In particular, pathway targeting for treating individuals who are at-risk of developing asmtha are described. In certain aspects, MLK1 inhibitors are used in treatment methods.
Type:
Application
Filed:
January 26, 2005
Publication date:
January 19, 2006
Applicant:
deCODE genetics ehf.
Inventors:
Hakon Hakonarson, Mark Gurney, Eva Halapi
Abstract: A role of the human PDE4D gene in stroke is disclosed. Methods for diagnosis, prediction of clinical course and treatment for stroke using polymorphisms in the PDE4D gene are also disclosed.
Abstract: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
Type:
Application
Filed:
January 30, 2004
Publication date:
December 22, 2005
Applicant:
deCODE Genetics ehf.
Inventors:
Anna Helgadottir, Mark Gurney, Jeffrey Gulcher, Hakon Hakonarson
Abstract: Linkage of myocardial infarction (MI) with a locus on chromosome 12q23 is disclosed. In particular, the LTA4H gene within this locus is shown by association analysis to be a susceptibility gene for MI. Methods for preventing and/or treating the recurrence of MI, in particular are described.
Type:
Application
Filed:
September 17, 2004
Publication date:
December 8, 2005
Applicant:
deCODE genetics ehf.
Inventors:
Anna Helgadottir, Mark Gurney, Hakon Hakonarson, Jeffrey Gulcher
Abstract: The current invention discloses methods for transforming a set of relations into multidimensional data cubes. A syntheses process is disclosed that dynamically and with minimal user input eliminates ambiguities when populating a data cube by introducing table-like virtual relations. The methods are generic and applicable to many data warehouse designs. The methods support relational OLAP for a wider variety of data and structures than possible using current relational implementation schemas.
Abstract: Association of Type II diabetes and a locus on chromosome 5 is disclosed. In particular, the gene KChIP1 within this locus is shown by linkage analysis to be a susceptibility gene for Type II diabetes. Pathway targeting for drug delivery and diagnosis applications in identifying those who have Type II diabetes or are at risk of developing Type II diabetes, in particular those that are non-obese are described.
Type:
Application
Filed:
April 7, 2004
Publication date:
September 29, 2005
Applicant:
deCODE genetics ehf.
Inventors:
Inga Reynisdottir, Jeffrey Gulcher, Struan Grant, Gudmar Thorleifsson
Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia.